Cadila Healthcare announced that the company has purchased 50% shares of Zydus BSV Pharma from Bharat Serums and Vaccines and now Zydus BSV has become 100% subsidiary of Cadila Healthcare.

Recently Zydus launched SoviHep, the breakthrough therapy for Hepatitis C in alliance with Gilead Sciences.

Shares of the company declined Rs 41.35, or 2.43%, to settle at Rs 1,661.25. The total volume of shares traded was 6,942 at the BSE (Thursday).